Evelo Biosciences, Inc.

NASDAQ:EVLO

$0.0005 USD

$0.0 (-16.67%)

Volume
2K
Average Volume
907
Market Capitalization
$9.49K
P/E Ratio
0.00
Dividend Yield
0.00%
Price Target
$
Year High
$0.41
Year Low
$0.00
Payout Ratio
$0.00
Current Ratio
$0.48

Industry, Sector & symbol

Stock Exchange NASDAQ Global Select
CEO Mr. Craig R. Jalbert CIRA
Industry Biotechnology
Sector Healthcare
Current Symbol EVLO
CUSIP 299734103
CIK 0001694665
Web https://www.evelobio.com
Phone 617 577 0300
Currency USD
Employees 66
Country US

Liquidity

Debt-to-Equity Ratio -1.27
Payout Ratio 0.00
Current Ratio 0.48
Quick Ratio 0.48
Cash Ratio 0.43

Sales & Book Value

Annual Sales $-
Price / Sales 0.00
Cash Flow -1.74
Price / Cash Flow 0.00
Price / Book 0.00

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 2 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-26.28
Trailing P/E Ratio 0.00
PEG Ratio 0.00
P/E Growth 0.00
Net Income $-114.53M
Net Margin 0.00%
Pretax Margin 0.00%
Return on Equity 91.90%
Return on Assets -162.25%

Financials Score

AltmanZ Score -53.44
Piotroski Score 2.00
Working Capital -20.82M
Total Assets 20.63M
Ebit -77.02M
Market Cap 9.49K
Total Liabilities 47.33M

Poll Results

About Evelo Biosciences, Inc. (NASDAQ:EVLO) Stock

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. ...

EVLO to Provide Dominion Energy With Safety Enhanced Energy Storage Systems

2024-11-20 08:00:00

MONTRÉAL--(BUSINESS WIRE)--EVLO Energy Storage Inc. (EVLO), a fully integrated battery energy storage systems (BESS) provider and wholly owned subsidiary of Hydro-Québec, announces a major achievement in its relationship with investor-owned utility Dominion Energy (Dominion) to develop a battery energy storage system (BESS) with enhanced fire and safety features that meet and exceed Dominion's unique safety specifications. The augmented version of EVLOFLEX now has achieved UL 9540 certification.

Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)

2023-10-20 08:15:02

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study

2023-10-18 12:47:41

Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.

Evelo Biosciences shares tank 46% after trial failure

2023-10-17 09:00:01

Evelo Biosciences' shares have tumbled 46% in premarket trading after the biotech firm revealed disappointing results in a phase II psoriasis trial for its next-generation drug, EDP2939. A resounding miss, the treatment failed to outperform the placebo, which has no therapeutic effect.

Evelo Biosciences to review options after Phase 2 trial of psoriasis treatment fails to meet main goal

2023-10-17 07:29:00

Evelo Biosciences Inc. EVLO, -6.73% said Tuesday it's reviewing its strategic options and exploring partnerships after a Phase 2 study of a treatment for psoriasis failed to meet its main goal. “The study's primary endpoint, the difference in the proportion of patients who achieved an outcome of a 50% improvement from baseline in Psoriasis Area and Severity Index (PASI) score (a PASI-50 response) between EDP2939 and placebo after 16 weeks of daily treatment, was not achieved,” the company said in a statement.

Frequently Asked Questions

What is the current Evelo Biosciences, Inc. (EVLO) stock price?

Evelo Biosciences, Inc.(NASDAQ:EVLO) stock price is $0.0005 in the last trading session. During the trading session, EVLO stock reached the peak price of $4 while $1.0E was the lowest point it dropped to. The percentage change in EVLO stock occurred in the recent session was --16.67% while the dollar amount for the price change in EVLO stock was -$-0.0.

EVLO's industry and sector of operation?

The NASDAQ listed EVLO is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of EVLO?

Mr. Craig R. Jalbert CIRA | President, Secretary, Principal Executive, Financial and Accounting Officer & Director
Dr. Mark Bodmer Ph.D. | Chief Scientific Officer and President of Research & Development
Ms. Leslie Wardwell-Scott Ph.D. | Vice President and Head of Corporate Development & Strategic Integration
Dr. Chun Zhang Ph.D. | Chief Technical Operations & Quality Officer
Ms. Jessica Cotrone | Vice President & Head of Communications

How many employees does EVLO have?

Number of EVLO employees currently stands at 66. EVLO operates from 620 Memorial Drive, Cambridge, MA 02139, US.

Link for EVLO official website?

Official Website of EVLO is: https://www.evelobio.com

How do I contact EVLO?

EVLO could be contacted at phone #617 577 0300 and can also be accessed through its website. EVLO operates from 620 Memorial Drive, Cambridge, MA 02139, US.

How many shares of EVLO are traded daily?

The average number of EVLO shares traded daily for last 3 months was 907.

What is the market cap of EVLO currently?

The market value of EVLO currently stands at $9.49K with its latest stock price at $0.0005